Legend Biotech · 2 days ago
Director of In Vivo Pharmacology
Philadelphia, PA
Full-time
Onsite
Director/Executive
8+ years expLegend Biotech is a global biotechnology company dedicated to treating and curing life-threatening diseases. They are seeking a Director of In Vivo Pharmacology to lead and expand in vivo research capabilities in support of their cell and gene therapy pipeline, overseeing preclinical pharmacology studies and guiding novel CAR-T candidates through development phases.
BiotechnologyHealth CareLife ScienceOncologyTherapeutics
Hiring Manager
Justin Kerno
Responsibilities
Lead the strategic direction and execution of in vivo pharmacology studies supporting cell or gene therapy development programs
Design, develop, and validate in vivo models (e.g., xenograft, syngeneic, orthotopic) to evaluate CAR-T efficacy, persistence, trafficking, and toxicity
Oversee in vivo study execution in-house and at CROs, ensuring scientific rigor, quality, and compliance with regulatory standards
Work cross-functionally with discovery, translational biology, immunology, and clinical teams to integrate pharmacodynamic, biomarker, and mechanism-of-action data
Interpret and present data to internal stakeholders, executive leadership, and external collaborators or partners
Author key sections of regulatory documents (e.g., INDs, Investigator’s Brochures, study reports)
Manage and mentor a team of scientists and research associates
Evaluate and implement emerging in vivo technologies and platforms to improve study throughput and translational relevance
The candidate has authority and should have the ability to make decisions on preclinical in vivo pharmacology strategies
Qualification
Required
PhD, DVM in Pharmacology, Immunology, or related field, with 8+ years of relevant industry experience
Deep expertise in in vivo models of cancer and/or immunotherapy; experience with CAR-T, TCR, or other cell or gene therapies highly preferred
Strong understanding of tumor immunology, immune cell trafficking, cytokine biology, and T cell kinetics
Proven track record of leading IND-enabling pharmacology studies
Hands-on experience with mouse handling, tumor implantation, IV/SC dosing, and tissue processing is preferred
Demonstrated ability to lead cross-functional teams and external CRO collaborations
Excellent written and oral communication skills, with the ability to present complex data to both technical and non-technical audiences
Strong leadership, mentoring, and project management skills
Preferred
Experience with CAR-T, TCR, or other cell or gene therapies highly preferred
Hands-on experience with mouse handling, tumor implantation, IV/SC dosing, and tissue processing is preferred
Benefits
Medical, dental, and vision insurance
401(k)-retirement plan with company match that vest fully on day one
Equity and stock options
Eight weeks of paid parental leave after just three months of employment
Paid time off policy that includes 15 vacation days, 5 personal days, 5 sick days, 11 U.S. national holidays, and 3 floating holidays
Flexible spending and health savings accounts
Life and AD&D insurance
Short- and long-term disability coverage
Legal assistance
Supplemental plans such as pet, critical illness, accident, and hospital indemnity insurance
Commuter benefits
Family planning and care resources
Well-being initiatives
Peer-to-peer recognition programs
Company
Legend Biotech
Legend Biotech is a biopharmaceutical company that develops and commercializes novel cell therapies for oncology.
1001-5000 employees
H1B Sponsorship
Legend Biotech has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (30)
2024 (11)
2023 (14)
2022 (7)
2021 (6)
2020 (13)
Funding
Current Stage
Public CompanyTotal Funding
$750.45M2023-05-05Post Ipo Equity· $350M
2022-07-25Post Ipo Equity· $250M
2020-06-05IPO
Leadership Team
Carlos Santos
Chief Financial Officer
Alan Bash
President, CARVYKTI
Recent News
2025-12-18
thefly.com
2025-12-09
Company data provided by crunchbase